Key Takeaway: Nurix is advancing its portfolio of therapies aimed at treating hematologic malignancies, particularly focusing on overcoming mutational resistance in BTK. The company emphasizes its commitment to translating scientific insights into effective treatments for cancer and autoimmune diseases. Their resources on protein degradation are available for further exploration.
Price reaction · baseline $9.47 (2023-09-20T14:36:00.000Z) · hit during market hours · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-2.5%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on novel scientific insights for breakthrough therapies.
Advancement of a multi-modal portfolio targeting cancer.
Commitment to addressing mutational resistance in BTK.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focused on in their research?
Nurix is focused on translating scientific insights into breakthrough therapies for cancer and autoimmune diseases.
How does Nurix address mutational resistance?
Nurix aims to overcome mutational resistance in BTK through targeted protein degraders.
What resources does Nurix provide?
Nurix offers resources related to protein degradation for further exploration.